Aarti Pharma

Aarti Pharmalabs achieved its highest ever quarterly profit on both standalone and consolidated bases in Q3 FY25. The consolidated top line grew by 20% YoY to ₹538 crores, driven by strong performance across all three business segments. EBITDA increased by 34% YoY to ₹129 crores, and Profit After Tax (PAT) saw a significant surge of 40% YoY, reaching ₹74 crores. This robust performance demonstrates the effectiveness of the company's strategic initiatives and execution capabilities.

The Xanthine derivatives segment recorded its highest ever quarterly volume sales, contributing 44% to the Q3 turnover. Despite competition from China and declining spot market prices, the company's long-term customer relationships and world-scale capacity enabled it to thrive, operating facilities at almost full capacity. The API and Intermediate business delivered its best quarterly revenue performance, accounting for 42% of the turnover, with 48% from regulated markets, 40% from ROW, and 12% from non-regulated markets, aligning with the focus on regulated markets.

The CDMO/CMO segment contributed 13% to the turnover in Q3. The company is currently working with 21 customers, adding two new ones this quarter, and managing 56 active projects, with 28 in commercial stages. Management expects to exceed last year's CDMO sales of ₹170 crores in FY25, despite having only achieved ₹76-78 crores in the first nine months. Significant growth is anticipated for FY26 due to a strong pipeline and manufacturing capabilities.

Brownfield expansion for Xanthine derivatives, increasing capacity from 5000 MT to 9000 MT, is progressing as planned, with regulatory filings for Tarapur unit three expected in the current quarter. The greenfield project at Atali, Gujarat, for CDMO/CMO and Intermediate manufacturing, with a 450 KL reactor capacity, is experiencing minor delays, with Phase-1 commissioning now targeted for Q1 FY26. The 21 MW solar energy project at Akola was commissioned in Q2 FY25, and another 9 MW project in Gujarat is expected in Q2 FY26, contributing to cost optimization and sustainability.

The company's EBITDA margin of approximately 24% in Q3 FY25 was supported by significant CDMO/CMO sales, activation of the solar energy project, and a one-time^📎 dividend income of ₹7 crores. Management is hopeful of replicating this performance in future quarters. The API segment benefits from a robust model with 70% backward integration, focusing on niche products like anticancer and steroids. A good pipeline of new API products is expected to commercialize in the next two to three years, with 12 new APIs under development.

Aarti Pharmalabs maintains a strong focus on R&D, spending close to 2% to 3% of revenue, supporting all three business segments. The company has filed 58 patents and operates three R&D centers dedicated to innovators, API business, and scale-up/cost-saving initiatives. This continuous innovation and cost-saving exercise are critical for remaining a significant player in its product categories and ensuring sustained growth.